Trump Administration Ready To Move Ahead On Marijuana Rescheduling, Four Months After President's Executive Order, Report Says

The Trump administration is reportedly preparing to move ahead with marijuana rescheduling, potentially issuing an announcement as soon as Wednesday after months of delay. The plan could restart the DEA hearing process and advance the proposed shift of cannabis from Schedule I to Schedule III under the Controlled Substances Act. The development is constructive for cannabis operators and advocates, though officials caution the timeline and final path could still change.

Analysis

The market is likely underpricing the second-order effect of regulatory clarity on capital access, not just the headline rescheduling outcome. Even a slow, procedural move toward Schedule III should improve the probability of lower effective tax burden, cleaner banking relationships, and a lower discount rate for cannabis operators whose equity value has been hostage to policy uncertainty rather than operating fundamentals. That matters most for firms with existing scale and near-term refinancing needs, because the re-rating can arrive before any real revenue inflection.

The bigger winner may be ancillary and non-plant-touching businesses that benefit from legalization-by-proxy without carrying the same regulatory overhang. Compliance software, payments, testing, packaging, and multi-state operators with strong retail footprints should all see incremental multiple support if federal risk perception falls, while weaker balance-sheet names are forced into a harder financing environment as capital rotates toward perceived winners. A more subtle effect is that lower policy risk could accelerate M&A, since strategic buyers can underwrite synergies with less fear of abrupt federal reversals.

Contrarian risk: the market may already be pricing a clean, linear process when the real path is likely messy and slow, with procedural challenges, further hearings, and potential political reversals stretching the timeline from days into months. Any re-opening of the administrative record could temporarily hurt the highest-beta cannabis names if investors had positioned for immediate implementation. The best setup is not a chase on the headline, but exposure to names that benefit from partial progress even if final reclassification slips.

From a broader political lens, this is also a signal that cannabis is becoming a leverage point for the administration’s pro-research, pro-deregulation messaging. That makes outright reversal less likely than a bureaucratic delay, but it also means the market should expect incrementalism rather than a one-and-done catalyst. In practice, that favors buying time through options or staged entries rather than aggressive outright longs into the first announcement.

Key Decisions for Investors

• Build a basket long in MSOS / GTBIF / CURLF on any post-announcement pullback over 1-3 weeks; use a 6-12 month horizon and size for a 2:1 upside/downside setup if federal process advances but remains slow.
• Prefer ancillary exposure via long GRWG or SCVL-style picks-and-shovels equivalents if liquidity is available; these names should benefit from policy normalization with less downside if the hearing process drags.
• Use call spreads rather than outright longs in high-beta cannabis names for the next 1-2 months; the trade is a volatility event, and procedural delays make premium decay a real risk.
• Pair long MSOS vs short a broad small-cap basket if available; this isolates regulatory re-rating from macro beta and captures the relative multiple expansion if cannabis-specific risk compresses.
• Avoid chasing the first gap higher; wait for confirmation of a formal administrative step, then add on 5-10% pullbacks because the next catalyst is likely procedural rather than immediate implementation.